Characteristics

Total (N = 101)

Mild forms (N = 58)

Severe forms (N = 43)

p-value

Demographics

Age (y.o.), median [min-max] 

67 [24-92]

66 [24-92]

64 [28-89]

0.32

Male, n (%)

61 (60%)

30 (52%)

31 (72%)

0.04

Body Mass Index, median [min-max]

27 [16-50]

26 [16-43]

27 (21-50)

0.32

Comorbidities

Hypertension, n (%)

45 (45%)

28 (48%)

17 (40%)

0.38

Diabetes, n (%)

18 (18%)

11 (19%)

7 (16%)

0.73

Tobacco use, n (%)

4 (4%)

2 (3%)

2 (5%)

0.76

Stroke, n (%)

9 (9%)

7 (12%)

2 (5%)

0.19

Dementia, n (%)

5 (5%)

4 (7%)

1 (2%)

0.29

Reduced autonomy, n (%)

9 (9%)

9 (16%)

0 (0%)

0.01

Treatments

Antiplatelets, n (%)

23 (23%)

17 (29%)

6 (14%)

0.11

Anticoagulant, n (%)

14 (14%)

8 (14%)

6 (14%)

1

Nonsteroidal Anti-inflammatory Drug, n (%) 

1 (1%)

1 (2%)

0 (0%)

0.39

Extra-neurological symptoms

Any extra-neurological symptoms, n (%)

98 (97%)

55 (95%)

42 (98%)

0.39

Fever, n (%)

70 (69%)

39 (67%)

31 (72%)

0.82

Throat pain, n (%)

2 (2%)

2 (3%)

0 (0%)

0.22

Cough, n (%)

81 (80%)

45 (78%)

36 (84%)

0.8

Dyspnea, n (%)

82 (81%)

44 (76%)

38 (88%)

0.11

Abdominal pain, n (%)

13 (13%)

10 (17%)

3 (7%)

0.13

Neurological symptoms

Any neurological symptoms, n (%)

75 (74%)

44 (76%)

31 (72%)

0.67

Central neurologic symptoms, n (%)

58 (57%)

35 (60%)

23 (53%)

0.49

Headache, n (%)

17 (17%)

12 (21%)

5 (12%)

0.23

Dizziness, n (%)

3 (3%)

3 (5%)

0 (0%)

0.13

Delirium, n (%)

29 (29%)

15 (26%)

14 (33%)

0.46

Ataxia, n (%)

1 (1%)

1 (2%)

0 (0%)

0.39

Seizure, n (%)

3 (3%)

3 (5%)

0 (0%)

0.13

Impaired consciousness, n (%)

24 (24%)

17 (29%)

7 (16%)

0.13

Peripheral neurologic symptoms, n (%)

40 (40%)

20 (34%)

20 (47%)

0.22

Smell impairment, n (%)

14 (14%)

6 (10%)

8 (19%)

0.23

Taste impairment, n (%)

23 (23%)

10 (17%)

13 (30%)

0.12

Skeletal muscular symptoms, n (%)

29 (29%)

16 (28%)

13 (30%)

0.77